William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sami Corwin has given his Buy rating due to a combination of factors that highlight the promising outlook for Arcellx Inc. The company has extended its cash runway into 2028, providing a solid financial foundation for future operations. This extension is supported by a clearer timeline for receiving milestone payments from Kite, which adds confidence to their financial projections.
Additionally, Arcellx’s upcoming presentation at the European Hematology Association Congress is expected to showcase comprehensive efficacy and safety data from their pivotal iMMagine-1 study. This data is anticipated to be a significant catalyst for the company’s stock, reinforcing the long-term therapeutic potential of their product, anito-cel. Furthermore, management’s insights suggest that potential tariffs will not significantly impact costs, maintaining favorable margins for the commercial launch of their product.
According to TipRanks, Corwin is a 3-star analyst with an average return of 1.3% and a 36.05% success rate. Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Krystal Biotech, and Allogene Therapeutics.